Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ANPEP | P15144 | 1/20 | 0.58 |
| ▸ | LTA4H | P09960 | 1/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | PKM | P14618 | 1/20 | 0.49 |
| ▸ | FNTA | P49354 | 4/20 | 0.48 |
| ▸ | FNTB | P49356 | 4/20 | 0.48 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.48 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL526076 | 1.00 | ANPEP (0.58) | ANPEPLTA4HGAAALDH1A1NPSR1 | |
| Hydrochloric Acid SCHEMBL29199142 | 0.98 | ANPEP (0.56) | ANPEPLTA4HGAAALDH1A1NPSR1 | |
| Hydrochloric Acid SCHEMBL30137695 | 0.98 | ANPEP (0.56) | ANPEPLTA4HGAAALDH1A1NPSR1 | |
| Acrylic Acid SCHEMBL1876772 | 0.92 | ANPEP (0.51) | ANPEPLTA4HGAAALDH1A1NPSR1 | |
| SCHEMBL7265651 | 0.88 | ANPEP (0.55) | ANPEPLTA4HGAA | |
| SCHEMBL3649405 | 0.87 | HTT (0.55) | ANPEPGAAFNTAFNTB | |
| SCHEMBL3649406 | 0.87 | HTT (0.55) | ANPEPGAAFNTAFNTB | |
| Acrylic Acid SCHEMBL17975813 | 0.86 | GAA (0.46) | ANPEPLTA4HGAAALDH1A1NPSR1 | |
| SCHEMBL30402768 | 0.86 | FNTA (0.56) | ANPEPLTA4HALDH1A1FNTAFNTB | |
| Hydrochloric Acid SCHEMBL1886525 | 0.85 | HTT (0.54) | ANPEPGAAFNTAFNTB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119954890-A | Optically pure small peptide chemiluminescent probe and application thereof in mycobacterium tuberculosis recognition | 广东工业大学 | 2025-05-09 | — | — | CN | disclosed |
| CN-113301920-B | Complexes comprising a ligand, a spacer, a peptide linker and a biomolecule | 安斯泰来制药株式会社 | 2025-01-14 | — | — | CN | disclosed |
| CN-116421782-B | Polyamino acid composite material with nerve repair promoting function, and preparation method and application thereof | 深圳大学 | 2024-11-12 | — | — | CN | disclosed |
| CN-116421782-A | Polyamino acid composite material with nerve repair promoting function, and preparation method and application thereof | 深圳大学 | 2023-07-14 | — | — | CN | disclosed |
| CN-108699108-B | Radiolabeled pharmaceutical | 国立大学法人千叶大学 | 2022-04-08 | — | — | CN | disclosed |
| US-20220105194-A1 | CONJUGATE COMPRISING LIGAND, SPACER, PEPTIDE LINKER, AND BIOMOLECULE | ASTELLAS PHARMA INC. (JP) | 2022-04-07 | — | — | US | disclosed |
| US-20220096653-A1 | CONJUGATE COMPRISING LIGAND AND CEACAM5 ANTIBODY FAB FRAGMENT | ASTELLAS PHARMA INC. (JP) | 2022-03-31 | — | — | US | disclosed |
| EP-2598160-A2 | STABILIZATION OF FSH | Ferring BV (NL) | 2013-06-05 | — | — | EP | disclosed |
| WO-2012013742-A2 | STABILIZATION OF FSH | FERRING B.V. (NL) | 2012-02-02 | — | — | WO | disclosed |
| EP-0853612-B1 | ALPHA-HYDRAZINO ACID DERIVATIVES AND METHOD FOR MAKING SAME | CENTRE NAT RECH SCIENT (FR) | 2000-06-14 | — | — | EP | disclosed |
| EP-0853612-A1 | ALPHA-HYDRAZINO ACID DERIVATIVES AND METHOD FOR MAKING SAME | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 1998-07-22 | — | — | EP | disclosed |
| WO-1997009303-A1 | ALPHA-HYDRAZINO ACID DERIVATIVES AND METHOD FOR MAKING SAME | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 1997-03-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220105194-A1 | CONJUGATE COMPRISING LIGAND, SPACER, PEPTIDE LINKER, AND BIOMOLECULE | MUC1, CA14, CA13 | ANPEP 127/4885LTA4H 3083/4885GAA 738/4885 |
| US-20220096653-A1 | CONJUGATE COMPRISING LIGAND AND CEACAM5 ANTIBODY FAB FRAGMENT | SIGLEC7, TNFSF11, FCGR2A | ANPEP 138/4885LTA4H 2973/4885GAA 704/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.